Karolinska Development company Umecrine Cognition to present at the EASL International Liver Congress 2017
STOCKHOLM - April 21, 2017. Karolinska Development's (Nasdaq Stockholm: KDEV) portfolio company Umecrine Cognition AB, whose novel orally-active GABA A receptor modulating steroid, GR3027, is in clinical development for hepatic encephalopathy (HE), will present clinical results from its Phase 1 study at The International Liver Congress TM 2017, the annual meeting of the European Association for the Study of the Liver, being held April 19-23, 2017, in Amsterdam, The Netherlands.
The poster, entitled "GR3027 reverses neurosteroid-induced GABAA receptor-mediated inhibition of brain function: A human challenge study", presents results of the human challenge part of the Phase 1a study designed to evaluate single-dose safety, tolerability and CNS target engagement of GR3027 in healthy adults. The challenge component involved a three-part cross-over design, in which healthy male subjects were randomized to receive placebo or two different doses of GR3027 prior to challenge. Its principle objective was to evaluate the ability of GR3027 to antagonize allopregnanolone-induced activation of GABAA as determined by its pharmacodynamic effects on two GABAA-modulated CNS functions, Saccadic Eye Velocity (SEV) and self-rated sedation using a Visual Analogue Scale (VAS).
Key findings presented in the poster include the following:
In predefined statistical analyses, GR3027 significantly inhibited the allopregnanolone-induced decrease in SEV (p=0.03; Wilcoxon Signed Rank Test); the results also provided evidence that GR3027 mitigates the impaired self-rated sedation produced by allopregnanolone.
In post-hoc statistical analyses that included only subjects who exhibited allopregnanolone-induced changes when pretreated with placebo, GR3027 significantly inhibited both the allopregnanolone-induced decrease in SEV (p=0.04; Wilcoxon Signed Rank Test) and allopregnanolone-induced sedation (p=0.01 and p=0.05 for low and high dose, respectively; Wilcoxon Signed Rank Test).
Enhanced GABAergic tone via neurosteroid-induced allosteric activation of GABAA receptors is emerging as critical to the pathogenesis of HE, prompting efforts to develop agents that antagonize GABAA receptor-potentiating neurosteroids . GR3027, a novel orally active small molecule designed to reduce GABAA receptor mediated inhibition of brain function by antagonizing endogenous inhibitory neurosteroids such as allopregnanolone, has been shown to be effective in animal models of HE , and the present findings demonstrate its ability to modulate the function of CNS GABAA receptors in humans. A Phase 1b/2a clinical study designed to assess safety, tolerability and PK of multiple ascending doses in healthy adults and patients with cirrhosis as well as preliminary exploration of the effect of GR3027 on cognitive function in cirrhotics is underway.
The poster will be presented on Friday, April 21, 2017, in Hall 1 session Cirrhosis and its complications: Clinical aspects, RAI Amsterdam Convention Center.
For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: email@example.com
Viktor Drvota, Deputy CEO and Chief Investment Officer, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: firstname.lastname@example.org
David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk
About Umecrine Cognition AB
Umecrine Cognition's GR3027 represents a first-in-class product against a target that is implicated in several major CNS-related disorders, including HE, a potentially life-threatening disorder with high and growing unmet medical need. For more information, please visit www.umecrinecognition.com
 Butterworth RF. 2016. Neurosteroids in hepatic encephalopathy: novel insights and new therapeutic opportunities. J Steroid Biochem Mol Biol., 160: 94-97.  Johansson M, Agusti A, Llansola M, Montoliu C, Strömberg J, Malinina E, Ragagnin G, Doverskog M, Bäckström T, Felipo V. GR3027 antagonizes GABAA receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2015; 309:G400-9
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
SEMAFO Inc. : Q4 and Annual 2017 Production and Costs in Line23.1.2018 00:59 | Pressmeddelande
Boungou 80% Complete - Continues on Time, on Budget MONTREAL, Jan. 22, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports 2017 production of 206,400 ounces at an all-in sustaining cost of $943 per ounce. As a result, the Corporation has beat its revised production and met its cost guidance for the year. Mana In the fourth quarter, Mana produced 49,500 ounces of gold at a total cash cost1 of $667 per ounce and all-in sustaining cost2 of $987 per ounce Annual production of 206,400 ounces, slightly ahead of 2017 guidance of 190,000 to 205,000 ounces Total cash cost1 for 2017 of $655 per ounce All-in sustaining cost2 for 2017 of $943 per ounce, in line with guidance of $920 to $960 per ounce Gold sales of 205,300 ounces generated 2017 revenues of $259 million ($1,261 per ounce) Mining Operations Mana, Burkina Faso Three-month period Year ended December 31, ended December 31, 2017 2016 Variation 2017 2016 Variation Tonnes processed 653,500 714,200 (8%) 2,739,900 2,753,300 - He
Atico Reports 2017 Fourth Quarter and Full Year Production Results22.1.2018 22:30 | Pressmeddelande
VANCOUVER, British Columbia, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSXV:ATY) (OTC:ATCMF) is pleased to announce operating results for the three and twelve month periods ended December 31, 2017 from its El Roble mine. Production totaled 5.33 million pounds of copper with 2,972 ounces of gold for the fourth quarter ("Q4 2017") and 20.63 million pounds of copper with 10,923 ounces of gold in concentrates for the full year 2017. "Atico has successfully concluded its fourth full year of operating the El Roble mine, exceeding 2017 guidance while achieving the highest annual production results to date," said Fernando E. Ganoza, CEO. "In the upcoming year, we will focus on increasing mineral resources through aggressive exploration at the El Roble mine and the surrounding prospective 6,600 hectare land package, to continue growing production and expanding the operation." Fourth Quarter and Full Year Operational Highlights Fourth Quarter Producti
Banque Fédérative du Credit Mutuel: Post Stabilisation Notice22.1.2018 18:54 | Pressmeddelande
PARIS, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Banque Fédérative du Credit Mutuel Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer: Banque Fédérative du Credit Mutuel Guarantor (if any): na Aggregate nominal amount: GBP 450,000,000 Description: 1.375% due Dec 2021 Offer price: 99.872 Stabilising Managers: HSBC & Goldman Sachs This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS The company news service from the London Stock Exchange Contacts: RNS Customer Services 0044-207797-4400 email@example.com http://www.rns.com This announ
Claroty Wins Inaugural S4 ICS Detection Challenge22.1.2018 18:42 | Pressmeddelande
Product Takes Top Spot in both Asset Discovery and Threat Detection Phases NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Claroty, an innovator in operational technology (OT) network protection, today announced that it was crowned winner of the inaugural S4 ICS Detection Challenge, which took place at the S4x18 Conference in Miami. Claroty's Continuous Threat Detection product claimed top honors in both the Phase I - Identification and Phase II - Detection segments of the challenge. During Phase I, contestants consumed network traffic captured from 15 different sites at an unidentified West Coast (U.S.) oil and gas company. The contestants were required to use their products to identify industrial control system (ICS) assets on the network and provide a view of how the assets were communicating. Contestants were rewarded for discovering assets, identifying specific details about them and were given bonus points for unique insights. Scoring was designed to test the products themselves, rat
CEO optimism booms despite increasing anxiety over threats to growth22.1.2018 18:30 | Pressmeddelande
· Optimism in global economic growth reaches record level and rises in all countries · US reinforces its lead on China as a target market for growth in 2018 · Over half of CEOs expect their headcount to increase · Terrorism, geopolitical uncertainty, cyber and climate change rise as threats to growth DAVOS, Switzerland, Jan. 22, 2018 (GLOBE NEWSWIRE) -- A record-breaking share of CEOs are optimistic about the economic environment worldwide, at least in the short term. That's one of the key findings of PwC's 21st survey of almost 1,300 CEOs around the world, launched today at the World Economic Forum Annual Meeting in Davos. Fifty seven percent of business leaders say they believe global economic growth will improve in the next 12 months. It's almost twice the level of last year (29%) and the largest ever increase since PwC began asking about global growth in 2012. Optimism in global growth has more than doubled in the US (59%) after a period of uncertainty surrounding the election (201
ShoCard Meets EU's GDPR 'Privacy by Design' Standards through its Identity Management Solutions22.1.2018 16:12 | Pressmeddelande
Blockchain-based identity management platform addresses provisions of EU data legislation CUPERTINO, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- ShoCard, a leading blockchain-based identity management system (IMS), today announces its technology meets the European Union's (EU) new regulatory framework for data, known as the General Data Protection Regulation (GDPR), "Privacy by Design" standards. The IMS removes the necessity for authentication data to be stored on organization databases. Instead, it is stored completely on the user's mobile device, secured with their private key and shared via the blockchain. Affected EU-based companies, as well as U.S.-based and other foreign-based companies, processing or holding the personal data of persons residing in the EU, no matter where they are located or where its data is processed within the region, are expected to have GDPR compliant solutions in place ahead of the legislation's enforcement date of May 25, 2018. With user privacy at the cor
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum